Regeneus surges on back of Progenza patent news
Clinical-stage regenerative medicine company Regeneus Ltd (ASX:RGS) announced on Monday morning that the US Patent and Trademark Office (USPTO) had issued a notice of allowance for issuance of a new key patent for the company’s lead stem cell platform technology Progenza.
This paves the way for the issue of a patent that would be applicable in the US.
Highlighting what a major development this is for Regeneus, the group’s shares were up more than 10% despite the S&P/ASX All Ordinaries (XAO) being down more than 400 points.
This payment was made under the terms of a non-binding memorandum of understanding negotiated with Kyocera at the start of the month providing the latter with exclusive negotiation rights to the Progenza platform technology for the treatment of knee osteoarthritis in Japan.
The new patent to be granted in the US covers the treatment of inflammatory conditions with the combination of stem cells and secretions.
This includes inflammatory conditions caused by a wide range of diseases, such as arthritis, heart disease, autoimmune conditions, respiratory diseases, asthma, Crohn's disease and other gastrointestinal diseases.
Patent also covers Acute Respiratory Distress Syndrome
The patent to be granted for Progenza also covers Acute Respiratory Distress Syndrome (ARDS), an inflammatory lung condition identified as a cause of death among patients diagnosed with COVID-19.
The success of Progenza on this front was recently documented in Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
ARDS is also a common cause of respiratory failure in critically ill patients.
Unlike pneumonia, there is no pharmaceutical treatment for ARDS23.
Notwithstanding the potential applications outside its core markets, Regeneus chief executive and executive director Leo Lee said, “While Regeneus’ focus remains on osteoarthritis and pain opportunities, this is a key patent which strengthens our intellectual property portfolio.
‘’It also opens doors to form partnerships for Progenza for other disease and indications.”
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.